VBLT - Vascular Biogenics Ltd.
| Previous Close | 1.44 |
| Open | 1.44 |
| Bid | 1.44 x 800 |
| Ask | 1.45 x 1200 |
| Day's Range | 1.42 - 1.47 |
| 52 Week Range | 1.32 - 9.05 |
| Volume | 44,083 |
| Avg. Volume | 138,284 |
| Market Cap | 52.028M |
| Beta (3Y Monthly) | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.40 |
| Earnings Date | Nov 12, 2018 - Nov 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- GlobeNewswire•8 days ago
Data Presented at ECTRIMS 2018 Show Potential of MOSPD2 as a Novel Target for Treatment of CNS Inflammation, Such as Multiple Sclerosis
VBL Therapeutics (Nasdaq: VBLT), announced today that a study entitled “MOSPD2: A Novel Therapeutic Target for the Treatment of CNS Inflammation,” is being presented today at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Berlin, Germany. The poster is being presented 5:15pm - 7:15pm CEST today, as part of Poster Session 2. VBL is developing its VB-600 platform of biologics targeting MOSPD2 for inflammatory and oncology indications. In MS, blood-borne monocytes constitute a part of the central nervous system (CNS)-infiltrating cells and are paramount for disease pathogenesis. VBL identified MOSPD2 (motile sperm domain–containing protein 2) as a protein which is predominantly expressed on the surface of human monocytes and is essential for their migration.
- GlobeNewswire•last month
VBL Therapeutics to Present at Upcoming Conferences in October
TEL AVIV, Israel, Sept. 17, 2018-- VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced ...
- GlobeNewswire•2 months ago
VBL Therapeutics Announces Publication of Positive New Data on its Lecinoxoid Drug Candidates for the Treatment of Renal Fibrosis
The paper, titled “Lecinoxoids for Renal Inflammation and Fibrosis,” describes the role of the Company’s lead lecinoxoid drug candidates, VB-201 and VB-703, in inhibiting toll-like receptor activation and monocyte migration in a model of focal segmental glomerulosclerosis (FSGS), thereby slowing kidney function decline. The recently granted U.S. Patent No. 10,022,388, entitled "Oxidized Lipids and Treatment or Prevention of Fibrosis", provides VBL with intellectual property protection for the use of Phase-2 ready candidate VB-201, and additional lecinoxoid candidates, for treatment of fibrosis until November 2035, before potential extensions.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of VBLT earnings conference call or presentation 16-Aug-18 12:30pm GMT
Q2 2018 Vascular Biogenics Ltd Earnings Call
- Benzinga•2 months ago
The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 15) Inspire Medical Systems Inc (NYSE: INSP ) Merck & Co., Inc. ...
- Zacks•2 months ago
Vascular Biogenics (VBLT) Reports Q2 Loss, Lags Revenue Estimates
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 27.78% and -40.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Vascular Biogenics: 2Q Earnings Snapshot
On a per-share basis, the Modi'In, Israel-based company said it had a loss of 13 cents. The gene therapy biotech company posted revenue of $180,000 in the period. The company's shares closed at $1.65. ...
- GlobeNewswire•2 months ago
VBL Therapeutics Announces Second Quarter 2018 Financial Results
Conference Call and Webcast at 8:30am Eastern Time Today. VBL is well capitalized, cash sufficient for more than 3 years, beyond key inflection points VBL continues development of VB-111 for Ovarian Cancer ...
- ACCESSWIRE•2 months ago
Vascular Biogenics Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 16, 2018 / Vascular Biogenics Ltd. (NASDAQ: VBLT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 16, 2018 at 8:30 AM Eastern ...
- GlobeNewswire•3 months ago
VBL Therapeutics to Report Second Quarter 2018 Financial Results on August 16
TEL AVIV, Israel, Aug. 01, 2018-- VBL Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced ...
- ACCESSWIRE•4 months ago
Breakfast Technical Briefing on Tesaro and Three Other Additional Biotech Stocks
LONDON, UK / ACCESSWIRE / June 20, 2018 / If you want a free Stock Review on TSRO sign up now at www.wallstequities.com/registration. Markets served include medical, agricultural, environmental, and industrial.Ahead of today's trading session, WallStEquities.com observes Teligent Inc. (NASDAQ: TLGT), Tesaro Inc. (NASDAQ: TSRO), Vascular Biogenics Ltd (NASDAQ: VBLT), and VistaGen Therapeutics Inc. (NASDAQ: VTGN).
- ACCESSWIRE•4 months ago
Today's Research Reports on Stocks to Watch: Enanta Pharmaceuticals and Vascular Biogenics
NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Enanta Pharmaceuticals as well as Vascular Biogenics were two stocks in the biotech arena making big moves in Wednesday's trading session. Enanta climbed higher ...
- Benzinga•4 months ago
Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 5) Haemonetics Corporation (NYSE: HAE ) Athersys, Inc. (NASDAQ: ...
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of VBLT earnings conference call or presentation 17-May-18 12:30pm GMT
Q1 2018 Vascular Biogenics Ltd Earnings Call
- Associated Press•5 months ago
Vascular Biogenics: 1Q Earnings Snapshot
On a per-share basis, the Or Yehuda, Israel-based company said it had a loss of 24 cents. The gene therapy biotech company posted revenue of $163,000 in the period. The company's shares closed at $2.23. ...
- ACCESSWIRE•5 months ago
Vascular Biogenics Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 17, 2018 / Vascular Biogenics Ltd. (NASDAQ: VBLT ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 17, 2018 at 8:30 AM Eastern Time. ...
- Zacks•6 months ago
Vascular Biogenics (VBLT) Enters Oversold Territory
Vascular Biogenics Ltd. (VBLT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
